IBL-302 - CAS 1414455-21-2

IBL-302 (AMU302), an orally available dual-signaling inhibitor targeting PIM and PI3K/AKT/mTOR, is effective against breast cancer and neuroblastoma. It has shown in vivo efficacy in a nude mouse xenograft model by combating trastuzumab resistance. Additionally, IBL-302 augments the effectiveness of widely used cytotoxic chemotherapy drugs such as cisplatin, doxorubicin, and etoposide [1] [2] [3].

PI3K, Akt, mTOR, Pim

Cytoskeletal Signaling, Chromatin/Epigenetic, PI3K/Akt/mTOR signaling, JAK/STAT signaling

1414455-21-2

C25H18FN5O4S3

567.64

CC=1C2=C3C(C=4SC(=CC4)CNC(=O)C=5C=C(S(=O)(=O)NC6=CC(C1S3)=CN=C6OC)C=CC5F)=NC=N2

-20°C

Ice Packs

Small Compound